XPC and hereditary clear cell renal cell carcinoma: Furthermore, the combination of AT-II and AT-III with FDA-approved drugs enhanced sensitivity in XPC-KD-resistant renal cell carcinoma (RCC) cells, overcoming XPC deficiency-mediated resistance [74].